The Effects of Trimetazidine on P-Wave Duration and Dispersion in Heart Failure Patients

Gunes Y., Tuncer M., Guntekin U., Akdag S., Gumrukcuoglu H. A.

PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, vol.32, no.2, pp.239-244, 2009 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 32 Issue: 2
  • Publication Date: 2009
  • Doi Number: 10.1111/j.1540-8159.2008.02208.x
  • Journal Name: PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.239-244
  • Keywords: trimetazidine, P-wave dispersion, heart failure, PAROXYSMAL ATRIAL-FIBRILLATION, ACUTE MYOCARDIAL-INFARCTION, ISCHEMIC CARDIOMYOPATHY, DIASTOLIC DYSFUNCTION, ELECTROCARDIOGRAPHY, VOLUME
  • Akdeniz University Affiliated: No

Abstract

Background: P-wave duration and dispersion (PWD) have been shown to be noninvasive predictors for development of atrial fibrillation. Thus, it may be possible to attenuate atrial fibrillation risk through normalization of P-wave duration and dispersion. Trimetazidine, a metabolic modulator, has been reported to improve cardiac function in heart failure (HF) patients.